🔗 Permalink

Inventor profile of:

Thomas N. Chase

City:

Washington, District of Columbia

Country:

United States

Published Applications:

Last publication date:

2026-03-12

Top Assignees for applications by Thomas N. Chase

The entities that hold a legal rights for patent applications filed by inventor Chase Thomas N.:

CHASE PHARMACEUTICALS CORPORATION 15 Washington, DC United States
CHASE THERAPEUTICS CORPORATION 13 Washington, DC United States
Chase Pharmaceuticals Corporation 8 Parsippany, NJ United States
AVION PHARMACEUTICALS, LLC 3 Alpharetta, GA United States
ALTO NEUROSCIENCE, INC. 3 Mountain View, CA United States
Chase Pharmaceuticals Corporation 3 Madison, NJ United States
NC MEDICAL RESEARCH INC. 3 Tokyo, Japan
CHASE THERAPEUTICS CORPORATION 2 Washington, United States
NC MEDICAL RESEARCH INC. 2 Minato-ku, Tokyo, Japan
Chase Parmaceuticals Corporation 1 Washington, DC United States
CHASE THERAPEUTICS CORPORATION 1 Washington, -

Recent patent applications by Chase Thomas N.

Thomas N. Chase from Washington, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-12

US20260069573A1

Human necessities

COMBINATION THERAPY FOR A DOPAMINE AGONIST

#2 | 2026-01-13

US19244143

Human necessities

Combination therapy for a dopamine agonist

#3 | 2025-10-23

US20250329454A1

Physics

DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS

#4 | 2023-11-02

US20230349906A1

Physics

KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS

#5 | 2023-07-27

US20230233496A1

Human necessities

Levodopa fractionated dose composition and use

#6 | 2022-07-07

US20220214360A1

Physics

ALPHA-SYNUCLEIN ASSAYS

#7 | 2022-06-02

US20220168281A1

Human necessities

NK-1 antagonist compositions and methods for use in treating depression

#8 | 2022-05-26

US20220160683A1

Human necessities

NK-1 antagonist compositions and methods for use in treating depression

#9 | 2022-03-10

US20220071976A1

Human necessities

DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION

#10 | 2022-01-06

US20220000854A1

Human necessities

DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE

#11 | 2021-12-23

US20210393595A1

Human necessities

ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES

#12 | 2021-11-04

US20210338652A1

Human necessities

COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS

#13 | 2021-07-22

US20210220308A1

Human necessities

Levodopa fractionated dose composition and use

#14 | 2020-12-24

US20200400687A1

Physics

METHODS FOR DEVELOPING PHARMACEUTICALS FOR TREATING NEURODEGENERATIVE CONDITIONS

#15 | 2020-12-24

US20200397761A1

Human necessities

Compositions and methods for treating synucleinopathies

#16 | 2020-12-03

US20200375957A1

Human necessities

COMPOSITIONS AND METHOD FOR TREATING DEPRESSION

#17 | 2020-12-03

US20200375956A1

Human necessities

Pharmaceutical combination and its use for treating synucleinopathties

#18 | 2020-08-13

US20200253893A1

Human necessities

MEMANTINE COMBINATIONS AND USE

#19 | 2020-06-04

US20200171014A1

Human necessities

OXYBUTYNIN-XANOMELINE TRANSDERMAL THERAPEUTIC SYSTEM COMBINATIONS

#20 | 2020-05-14

US20200147097A1

Human necessities

NK1-antagonist combination and method for treating synucleinopathies

#21 | 2020-05-14

US20200147053A1

Human necessities

NK-1 antagonist compositions and methods for use in treating depression

#22 | 2020-05-07

US20200138792A1

Human necessities

PHARMACEUTICAL COMBINATIONS OF ZONISAMIDE AND PRAMIPEXOLE, AND RELATED METHODS, FOR TREATING SYNUCLEINOPATHIES

#23 | 2020-04-23

US20200121656A1

Human necessities

METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA

#24 | 2020-04-23

US20200121626A1

Human necessities

Levodopa fractionated dose composition and use

#25 | 2020-04-16

US20200113899A1

Human necessities

STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES

#26 | 2020-01-16

US20200016127A1

Human necessities

Compositions and methods for treating synucleinopathies

#27 | 2019-12-05

US20190365736A1

Human necessities

ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS

#28 | 2019-10-17

US20190314354A1

Human necessities

MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM

#29 | 2019-09-05

US20190269627A1

Human necessities

MEMANTINE COMBINATIONS AND USE

#30 | 2019-03-28

US20190091214A1

Human necessities

USE AND COMPOSITION FOR TREATING DEMENTIA

#31 | 2019-01-03

US20190000826A1

Human necessities

ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS

#32 | 2018-12-20

US20180360845A1

Human necessities

MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS

#33 | 2018-12-13

US20180353577A1

Human necessities

Cell therapy for the treatment of neurodegeneration

#34 | 2018-10-18

US20180296540A1

Human necessities

METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA

#35 | 2018-09-06

US20180250270A1

Human necessities

MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM

#36 | 2018-05-03

US20180116979A1

Human necessities

Memantine combinations and use

#37 | 2018-02-22

US20180050023A1

Human necessities

Oxybutynin-xanomeline transdermal therapeutic system combinations

#38 | 2018-02-22

US20180050018A1

Human necessities

PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION

#39 | 2018-02-22

US20180050008A1

Human necessities

Oxybutynin transdermal therapeutic system muscarinic agonist combination

#40 | 2017-11-16

US20170326211A1

Human necessities

Cell therapy for the treatment of neurodegeneration

#41 | 2017-11-02

US20170312259A1

Human necessities

Method and composition for treating Alzheimer-type dementia

#42 | 2017-03-30

US20170087142A1

Human necessities

Anticholinergic neuroprotective composition and methods

#43 | 2016-12-29

US20160375001A1

Human necessities

Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system

#44 | 2016-08-25

US20160243070A1

Human necessities

Oxybutynin transdermal therapeutic system combination

#45 | 2016-05-26

US20160143890A1

Human necessities

Method and composition for treating alzheimer-type dementia

#46 | 2015-08-20

US20150231122A1

Human necessities

Anticholinergic neuroprotective composition and methods

#47 | 2015-08-13

US20150224096A1

Human necessities

USE AND COMPOSITION FOR TREATING DEMENTIA

#48 | 2015-07-23

US20150203452A1

Chemistry; metallurgy

Piperidinium quaternary salts

#49 | 2015-01-01

US20150005292A1

Human necessities

Method and composition for treating alzheimer-type dementia

#50 | 2014-12-04

US20140356343A1

Human necessities

COMPOSITION FOR TREATING PARKINSON'S DISEASE

#51 | 2014-09-25

US20140288057A1

Human necessities

Method and composition for treating alzheimer-type dementia

#52 | 2014-09-18

US20140275036A1

Human necessities

Use and composition for treating dementia

#53 | 2014-08-07

US20140219969A1

Chemistry; metallurgy

Cell therapy for the treatment of neurodegeneration

#54 | 2013-06-20

US20130158012A1

Human necessities

USE AND COMPOSITION FOR TREATING DEMENTIA

#55 | 2011-08-18

US20110201597A1

Human necessities

METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA

#56 | 2011-03-24

US20110071135A1

Human necessities

Method and composition for treating alzheimer-type dementia

#57 | 2011-01-27

US20110021503A1

Human necessities

Use and composition for treating dementia

InventorID:

301126 ⎘